OKYO Pharma Limited announced it received $1.4 million in non-dilutive funding. This financial funding strengthens the company’s ability to advance its pipeline without diluting shareholder value, the company said in a press release. 

OKYO Pharma said the funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on OKYO’s lead program, OK-101 focused on treating neuropathic corneal pain (NCP). NCP is a condition that causes pain and sensitivity of the eyes, face or head. It can exhibit as a severe, chronic or debilitating condition in patients suffering from a host of ophthalmic conditions. 

According to the company, OK-101 showed clear statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and is presently being evaluated in a randomized, placebo-controlled, double-masked Phase 2 trial to treat 48 NCP patients.

OKYO Pharma said the infusion of non-dilutive funding underscores the company's commitment to maintaining fiscal responsibility while pursuing transformative therapies that address critical unmet medical needs.